Skip to main content

Table 2 Standardized incidence ratios and excess risk for the diagnosis of t-AML after lung cancer

From: Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia

Characteristic n (%) SIR (95% CI) ER (per 10,000) Person-years at risk
Sex
 Male 52 (50.0) 3.20 (2.41–4.16)* 3.26 116,136.88
 Female 52 (50.0) 5.36 (4.03–7.00)* 4.10 107,177.52
Age
 < 65 years 58 (55.8) 9.08 (6.74–11.97)* 4.24 104,996.47
 ≥ 65 years 46 (44.2) 2.71 (2.07–3.50)* 3.15 118,317.93
Latency period
 2–11 months 11 (10.6) 1.12 (0.56–2.00) 0.13 86,808.04
 12–35 months 41 (39.4) 5.35 (3.87–7.21)* 5.15 67,848.48
 36–59 months 31 (29.8) 9.29 (6.35–13.11)* 10.54 27,090.39
 60+ months 21 (20.2) 3.88 (2.46–5.82)* 4.11 41,567.48
Period of diagnosis
 1975–1984 7 (6.7) 5.99 (2.41–12.35)* 4.26 13,687.57
 1985–1994 12 (11.5) 4.19 (2.23–7.17)* 3.01 32,838.60
 1995–2004 29 (27.9) 4.05 (2.73–5.78)* 3.61 62,575.81
 2005–2015 56 (53.8) 3.79 (2.88–4.88)* 3.80 114,212.42
  1. ER Excess risk, t-AML Therapy-related acute myeloid leukaemia, SIRs Standardized incidence ratios
  2. * Indicates P < 0.05
\